DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE
Pre-Launchdolutegravir, emtricitabine and tenofovir alafenamide
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing dolutegravir (integrase inhibitor), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor) for the treatment of HIV-1 infection. The three-in-one oral formulation combines complementary antiretroviral mechanisms to suppress viral replication. This product represents a generic or authorized generic entry into the established HIV treatment market.
Pre-Launch
Pre-launch stage indicates active commercial build-out; hire focus likely on market access, field sales, and launch planning teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Employment in this product area will primarily involve launch execution and market penetration in the competitive HIV space. Roles will focus on defending market share against branded competitors and capturing price-sensitive, international, and underserved patient populations through generic/authorized generic positioning.
Brand ManagerMarket Access Manager
Worked on DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.